Climb Bio (CLYM) Return on Capital Employed (2021 - 2026)
Climb Bio (CLYM) posted Return on Capital Employed of 38.51% for Q1 2026, up 4.66% on a QoQ basis from 40.4% in Q4 2025, and up 1202.0% year-over-year from 2.96% in Q1 2025.
Climb Bio (CLYM) Return on Capital Employed (2021 - 2026) Analysis & Trends
Climb Bio's Return on Capital Employed history runs 6 years deep, the most recent figure standing at 38.51% for Q1 2026.
- Quarterly Return on Capital Employed rose 1202.0% year-over-year to 38.51% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 38.51% (up 1202.0% YoY) and the FY2025 annual result came in at 36.6%, up 1502.0% from the prior year.
- Return on Capital Employed was 38.51% for Q1 2026 at Climb Bio, up from 40.4% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 18.55% in Q1 2024 and bottomed at 50.53% in Q1 2025.
- A 5-year average of 36.14% and a median of 37.03% in 2023 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2024 — Return on Capital Employed surged 2629 bps — and 2025, when it plunged 3198 bps.
- Climb Bio's Return on Capital Employed stood at 34.24% in 2022, then fell by 8 bps to 37.03% in 2023, then slipped by 3 bps to 38.19% in 2024, then slipped by 6 bps to 40.4% in 2025, then climbed by 5 bps to 38.51% in 2026.
- Business Quant data shows CLYM's Return on Capital Employed at 38.51% in Q1 2026, 40.4% in Q4 2025, and 32.62% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Climb Bio | 870.33 Mn | 870.33 Mn | - | -38.51% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -38.51% |
| Dec 31, 2025 | -40.40% |
| Sep 30, 2025 | -32.62% |
| Jun 30, 2025 | -29.60% |
| Mar 31, 2025 | -50.53% |
| Dec 31, 2024 | -38.19% |
| Sep 30, 2024 | -34.54% |
| Jun 30, 2024 | -42.39% |
| Mar 31, 2024 | -18.55% |
| Dec 31, 2023 | -37.03% |
| Sep 30, 2023 | -40.06% |
| Jun 30, 2023 | -41.93% |
| Mar 31, 2023 | -44.85% |
| Dec 31, 2022 | -34.24% |
| Sep 30, 2022 | -33.25% |
| Jun 30, 2022 | -31.56% |
| Mar 31, 2022 | -26.05% |
| Dec 31, 2021 | -20.77% |
| Sep 30, 2021 | -28.76% |